Abstract
Bleomycin plus etoposide and cisplatin seem to be a promising alternative for women with ovarian cancer. We are reporting two cases with favorable pregnancy outcome after exposure to these chemotherapeutic agents at the second and third trimesters of pregnancy. A pregnant woman with a stage Ic yolk-sac tumor underwent a right oophorectomy with omentectomy, and received five cycles of bleomycin, etoposide and cisplatin from the 22nd week of pregnancy until delivery. The second case was a pregnant woman with a stage Ia immature teratoma who underwent right salpingo-oophorectomy and received two cycles of bleomycin, etoposide and cisplatin starting at 30th week of pregnancy. The two patients did not have any evidence of recurrence of ovarian cancer for 6 and 2 years, respectively. Their babies did not have any evidence of minor or major malformations, and showed normal neurological development at 6 and 2 years of follow-up, respectively.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Bleomycin / adverse effects
-
Bleomycin / therapeutic use
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Cisplatin / therapeutic use
-
Endodermal Sinus Tumor / diagnosis
-
Endodermal Sinus Tumor / drug therapy*
-
Etoposide / administration & dosage
-
Etoposide / adverse effects
-
Etoposide / therapeutic use
-
Female
-
Humans
-
Infant, Newborn
-
Male
-
Ovarian Neoplasms / diagnosis
-
Ovarian Neoplasms / drug therapy*
-
Pregnancy
-
Pregnancy Complications, Neoplastic / diagnosis
-
Pregnancy Complications, Neoplastic / drug therapy*
-
Pregnancy Outcome*
-
Teratoma / diagnosis
-
Teratoma / drug therapy*
Substances
-
Bleomycin
-
Etoposide
-
Cisplatin